A limitation of this study is that tasquinimod, the inhibitor for S100A9, and AMD3465, which blocks the cell surface binding of CXCL12 to CXCR4, are currently under clinical trial and has been not approved for cancer therapy yet. Here, CXCL12 is linked to cancer.